ESMO 2019 | Sym015: MET antibody mixture for advanced solid tumors

Ross Camidge

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase 1a/2a trial of Sym015, a MET antibody mixture, in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter